Frankfurt
11.11.26 | 08:03
0,042 Euro
+1,69 % +0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| Fr | Klaria Pharma Holding AB: Klaria announces last subscription date in the Company's rights issue | 173 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that today, 6 November 2026, is the last day of subscription in the Company's rights issue of units of up to approx. SEK 147.6 million... ► Artikel lesen | |
| Do | Klaria Pharma Holding AB: Klaria Pharma: The company's present value is approx. SEK 812 million in external valuation, corresponding to approx. SEK 1.88 per share after completion of the rights issue | 116 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Honeybadger has today published a valuation report that has been prepared on behalf of and against remuneration from Klaria.... ► Artikel lesen | |
| 30.10. | Klaria Pharma Holding AB: Klaria advances collaboration with BDO's Life Science M&A team through launch in Europe and completed strategic US plan | 234 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") today publishes a status update regarding licensing partner CNX Therapeutics' ("CNX") upcoming launch of Sumatriptan Alginate Film ("SAF")... ► Artikel lesen | |
| 26.10. | KLARIA PHARMA HOLDING AB: Klaria publishes digital Q&A session with the company's CEO and chairman of the board | 4 | Cision News | ||
| 22.10. | KLARIA PHARMA HOLDING AB: Klaria receives additional subscription commitments and extends the subscription period in the Company's rights issue | 1 | Cision News | ||
| 22.10. | KLARIA PHARMA HOLDING AB: Klaria plans digital Q&A session with the company's CEO and chairman of the board | 1 | Cision News | ||
| 20.10. | KLARIA PHARMA HOLDING AB: Klaria's chairman interviewed on the upcoming European launch of SAF and the potential in the U.S. | 1 | Cision News | ||
| 16.10. | Klaria Pharma Holding AB: Klaria Pharma: External valuation estimates peak sales for Sumatriptan Alginate Film at approx. USD 500 million per year | 425 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company today publishes a summary of an external valuation of Klaria's leading project carried out by L.E.K Consulting.... ► Artikel lesen | |
| 14.10. | Listing Of Units Rights And Paid Subscription Units Of Klaria Pharma Holding AB | 520 | GlobeNewswire | With effect from October 15, 2026, the units rights in Klaria Pharma Holding AB will be traded on First North Growth Market. Trading will continue up until and including October 23, 2026.
... ► Artikel lesen | |
| 13.10. | KLARIA PHARMA HOLDING AB: KLARIA PHARMAISHES PROSPECTUS IN CONNECTION WITH RIGHTS ISSUE OF APPROXIMATELY SEK 147.6 MILLION | 3 | Cision News | ||
| 13.10. | Klaria Pharma Holding AB: Klaria Pharma Publishes Prospectus In Connection With Rights Issue Of Approximately Sek 147.6 Million | 205 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE... ► Artikel lesen | |
| 08.10. | Klaria Pharma Holding AB: Klaria has secured subscription and underwriting commitments equivalent to approximately 75.3 percent of the rights offering, as well as bridge financing of approximately SEK 30.7 million | 209 | GlobeNewswire (Europe) | NOT FOR PUBLIC DISCLOSURE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 08.10. | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.10.2026 | 335 | Xetra Newsboard | Das Instrument 0PD0 GB00BSB7BS06 PINEWOOD TECH.GR. LS 1,0 EQUITY wird cum Kapitalmassnahme gehandelt am 08.10.2026 und ex Kapitalmassnahme am 09.10.2026 The instrument 0PD0 GB00BSB7BS06 PINEWOOD TECH.GR.... ► Artikel lesen | |
| 05.10. | Klaria Pharma Holding AB: Report from Extraordinary General Meeting of Klaria Pharma Holding AB (publ) | 210 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), reg.no. 556959-2917. Below is a summary of the resolutions adopted by the Extraordinary General Meeting (all in accordance... ► Artikel lesen | |
| 14.09. | KLARIA PHARMA HOLDING AB: Documents for the extraordinary general meeting will be available no later than September 21, 2026. | 2 | Cision News | ||
| 07.09. | Klaria Pharma Holding AB: Klaria and RTHS enter collaboration agreement for the development of early migraine detection and treatment | 250 | GlobeNewswire (Europe) | Klaria AB and Gothenburg-based RTHS have entered a collaboration agreement that aims to exploit RTHS sensor-based blood dynamics measurements to detect migraine prior to symptoms appearing in patients.... ► Artikel lesen | |
| 01.09. | Klaria Pharma Holding AB: Klaria Interim Report Q2 2026 | 200 | GlobeNewswire (Europe) | Summary of interim reportSecond quarter of 2026
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for the quarter amounted to 4.4 MSEK... ► Artikel lesen | |
| 01.09. | Summons to extraordinary general meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 01.09. | Klaria Pharma Holding AB (publ) calls an Extraordinary General Meeting to resolve on a Rights Issue of units and an amendment of the Articles of Association | 1 | Cision News | ||
| 01.09. | Klaria Pharma Holding AB Q2 Loss Narrows | 1 | RTTNews |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 55,37 | -1,58 % | Beste DAX-Aktie des Jahres!: Bayer: Ist die US-Zulassung für Asundexian der nächste Kurstreiber | © Foto: Hendrik Schmidt - dpa-ZentralbildEin günstiger Beipackzettel und ein Preis im Rahmen der Erwartungen: Die Bank of America sieht im neuen Bayer-Medikament Asundexian deutlich mehr Potenzial,... ► Artikel lesen | |
| DERMAPHARM | 38,825 | +0,84 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
| INCYTE | 108,30 | +0,98 % | Incyte präsentiert auf der ASH 2026 neue Daten, die die Fortschritte im gesamten hämatologischen Portfolio verdeutlichen | Zu den neuen Daten zu myeloproliferativen Neoplasien (MPN) gehören INCA033989, Incytes "First-in-Class"-monoklonaler Antikörper, der auf mutiertes Calreticulin (mutCALR) abzielt, bei der Erstlinienbehandlung... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 5,690 | -3,89 % | Green Thumb Indus Q3 2026 Earnings Call Transcript | ||
| COSMO | 62,00 | -1,12 % | Cosmo Pharmaceuticals N.V.: Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis | Ad hoc announcement pursuant to Art. 53 LR 46.2% clinical remission with rifamycin 1% topically acting gel vs 14.3% with placebo (p=0.0190). The therapy represents a new non-immune... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,700 | +2,67 % | Sellas Life Sciences Group: Regal erreicht die nächste Marke - was folgt jetzt? | ||
| OPKO HEALTH | 1,550 | +0,65 % | Opko sees FY 2026 continuing-ops revenue of $268M-$278M following $722M LabCorp asset sale agreement | ||
| OXFORD BIOMEDICA | 6,700 | 0,00 % | Oxford Biomedica PLC - OXB to present at Jefferies Healthcare Conference | ||
| SUMITOMO PHARMA | 10,362 | -2,23 % | Sumitomo Pharma, Novo Nordisk Win Japan Nod For Wegovy In MASH | TOKYO (dpa-AFX) - Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,498 | +1,06 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| VETOQUINOL | 86,70 | +0,12 % | Vetoquinol: Sales at End September 2026 | 9-months sales: €399 million (+5.4% at constant exchange rates and +3.9% on a reported basis)
9-month sales of Essential Products: €259 million (+6.0% at constant exchange rates and +6.7% on a... ► Artikel lesen | |
| ASTRID INTELLIGENCE | 0,001 | 0,00 % | Astrid Intelligence - Subnet 127 update: Zils and OTC token sale | ||
| BIOHARVEST SCIENCES | 1,430 | -3,38 % | BioHarvest Sciences Inc.: BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026 | Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical... ► Artikel lesen | |
| OCUMENSION THERAPEUTICS | 0,555 | -0,89 % | NICOX SA: Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension | Press Release Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
Ocumension has submitted the New Drug Application (NDA) to the Chinese National Medical Products Administration... ► Artikel lesen | |
| BAYER | 56,42 | -1,16 % | Bayer-Aktie mit deutlichem Kursanstieg - 50-EUR-Marke im Blick | Nach der Verteidigung der 200-Tage-Linie hat die Bayer-Aktie eine weitere Widerstandszone überwunden. Begleitet wurde der Kursanstieg von einem erhöhten Handelsvolumen und positiven Entwicklungen im... ► Artikel lesen |
Das Unternehmen KLARIA PHARMA HOLDING AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+1,69 %) liegt der Kurs bei 0,042 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.